BioSpace News Archive

PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today the closing of its previously announced registered direct offering.

Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced today an agreement with CarePICS, the latest resource addition to Fuse’s comprehensive portfolio and biologics product offerings for wound care.

National Health Investors, Inc. provided a business update regarding its monthly contractual cash collections and average occupancy from its three largest senior housing operators.

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI® (crizotinib) for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.

Demonstrating its commitment to advancing the next generation of palliative care leaders and ensuring people with serious illness and their caregivers live well

Teva Announces Launch of a Generic Version of NuvaRing ® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States

CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout and Duchenne community needs.

Qilian International Holding Group Limited (the “Company”) (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, today announced the closing of its initial public offering (“Offering”) of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.

BT7480 on track for Phase I trial start in 2H ’21; early immuno-oncology discovery has resulted in new programs targeting natural killer cells, which are now moving into lead optimization

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in an oral symposium and three poster presentations during the 2021 American Professional Society of ADHD and Related Disorders (APSARD) Vi